首页> 外文期刊>Journal of hypertension >Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension
【24h】

Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension

机译:醛固酮和利尿剂阻断剂与双重肾素-血管紧张素阻断剂对顽固性高血压患者左心室质量消退的疗效更高

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: We report the results of an echocardiographic substudy carried out in a trial comparing the effects of two different treatment strategies - mineralocorticoid receptor blockade (MRB) and dual renin-angiotensin system blockade (RASB) - in patients with resistant hypertension. Both strategies reduce left ventricular mass index (LVMI), but they have not been compared in patients with resistant hypertension. Methods: After 4-week treatment with 300 mg irbesartan + 12.5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5mg ramipril (RASB group, n = 40) groups for 12 weeks. Treatment intensity was increased at week 4, 8 or 10 if home blood pressure (BP) was equal to or above 135/85 mmHg, by sequentially adding 20-40 mg furosemide and 5mg amiloride (MRB group), or 10mg ramipril and 5-10 mg bisoprolol (RASB group). Transthoracic echography was performed at baseline and week 12.
机译:目的:我们报告了一项超声心动图子研究的结果,该研究比较了两种不同的治疗策略-盐皮质激素受体阻滞剂(MRB)和双重肾素-血管紧张素系统阻滞剂(RASB)对耐药性高血压患者的疗效。两种策略均可以降低左心室质量指数(LVMI),但尚未在抵抗性高血压患者中进行比较。方法:在接受300 mg厄贝沙坦+ 12.5 mg氢氯噻嗪+ 5 mg氨氯地平4周治疗后,将86例耐药性高血压患者随机分为25 mg螺内酯(MRB组,n = 46)或5mg雷米普利(RASB组, n = 40)组,共12周。如果家庭血压(BP)等于或高于135/85 mmHg,则在第4、8或10周增加治疗强度,方法是依次添加20-40 mg速尿和5mg阿米洛利(MRB组)或10mg雷米普利和5- 10 mg比索洛尔(RASB组)。在基线和第12周进行经胸超声检查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号